Steven Limentani

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology · 2004 · 740 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Paul G. Richardson, Hannah Briemberg, Sundar Jagannath et al. · Journal of Clinical Oncology · 2006 · 650 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17